Home
APONTIS PHARMA

APONTIS PHARMA Market Share Analysis for June 2026

APONTIS PHARMA - unser Name ist bewusst gewählt. Wir sehen uns als Brückenbauer, vernetzen Ärzte und Patienten, Partner und gesundheitliche Institutionen.

Industry: N/A

Domainapontis-pharma.de

Year Founded2006

Employees51 - 200

Annual Revenue$5M - $10M

APONTIS PHARMA

APONTIS PHARMA (including company regionals)

apontis-pharma.de

See more website traffic and engagement information

APONTIS PHARMA Revenue up to June 2026 is 5M - 10M

revenue generated by APONTIS PHARMA top domains

APONTIS PHARMA top domains revenue over 3 years

Revenue for APONTIS PHARMA top domains

apontis-pharma.de5M - 10M

See more with Sales Intelligence

Total visits to APONTIS PHARMA's top domains

Understand APONTIS PHARMA market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

apontis-pharma.de1.1K

See more with Sales Intelligence

Avg. visit duration in APONTIS PHARMA's top domains

Analyze APONTIS PHARMA engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

apontis-pharma.de00:00:51

See more with Sales Intelligence

Avg. pageviews on APONTIS PHARMA's top domains

See how APONTIS PHARMA keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

apontis-pharma.de2.16

See more with Sales Intelligence

APONTIS PHARMA top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by APONTIS PHARMA

These are the website technologies, by industry, used by APONTIS PHARMA top domains

Advertising (2)

DoubleClick

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

Audio Video Media (1)

Vimeo

More Technologies

4

See all

News & Signals from APONTIS PHARMA

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsApontis Pharma Ag hired Wohlschlegel as CEO on Sep 1st '23.Wohlschlegel was appointed CEO of APONTIS PHARMA in september 2023 to implement the restructuring of the company and achieve a return to profitability based on a long-term growth strategy.

NewsApontis Pharma Ag partners with Novartis Pharmaceuticals Corporation.APONTIS PHARMA AG ("" or the "Company", Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of two medications in the asthma indication for Germany.

NewsApontis Pharma Ag launched Single Pill products alone on Jan 1st '13.Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention.